Featured Issue Briefs
The Battle on the Home Front: Jonathan Gadsden's Story
Marine Lance Corporal's story reflects the growing need for new antibiotics that can treat dangerous diseases, against which most drugs are useless. Read More
Facilitating Medical Device Innovation: De Novo Reform
The de novo process -- which requests lower-risk reclassification of medical devices and entry into the marketplace -- as it exists now is not achieving its purpose and has instead added unnecessary and time-consuming requirements. Read More
Food Products Recalled by FDA
Since President Obama signed the FDA Food Safety Modernization Act into law, at least 149 FDA-regulated food products have been recalled due to potential pathogenic contamination. Read More
More Issue Briefs
| Date | Issue Briefs | Topic |
|---|---|---|
| Apr 18, 2012 |
Testimony before the Committee on Energy and Commerce Subcommittee on HealthU.S. House of Representatives PDF Download Since 1992, user fee agreements have given FDA significant and sustained resources that allow the agency to review new products quickly. In fact, preliminary findings of a study that Pew has funded show that FDA reviews new drugs faster than its cou More info |
Drug Safety |
| Apr 13, 2011 |
Testimony before the Committee on Energy on Commerce, Subcommittee on Oversight and Investigations, United States House of Representatives"Chairman Stearns, Ranking Member DeGette, and members of the Oversight and Investigations Subcommittee, thank you for the opportunity to submit testimony about the essential steps Congress must take to protect Americans and ensure the integrity of our drug supply..." More info |
Drug Safety |
| Mar 8, 2012 |
Testimony before the House Committee on Energy and Commerce, Subcommittee on HealthAllan Coukell, Director of Medical Programs, and Sharon Ladin, Director of the Antibiotics and Innovation Project, testify before the House Committee on Energy and Commerce, Subcommittee on Health on stimulating the development of new antibiotics urgently needed to fight serious and life-threatening bacterial infections. More info |
Drug Safety, Antibiotic Innovation |
| Mar 29, 2012 |
Testimony before the Senate Committee on Health, Education, Labor and PensionsAllan Coukell, Director of Medical Programs, Pew Health Group: Chairman Harkin, Ranking Member Enzi, and members of this committee, thank you for the opportunity to testify about the importance of the user fee agreement legislation to patients. More info |
Drug Safety, Drugs and Devices at the FDA |
| Jul 25, 2012 |
Testimony of Allan Coukell Before the Committee on Commerce, Science and TransportationPew's Allan Coukell submitted a statement of record to the Congressional Committee on Commerce, Science and Transportation regarding concerns with the pharmaceutical supply chain. The focus of Coukell's testimony was the drug distribution system – the weaknesses in the system and the risks of counterfeit and stolen drugs. More info |
Drug Safety |
| Feb 1, 2012 |
Testimony of Allan Coukell before the Committee on Energy and Commerce, Subcommittee on Health, United States House of Representatives"Pew has been working to identify the risks to the drug supply and advance pragmatic solutions. In July of 2011, we released a report entitled “After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs." More info |
Drug Manufacturing and Distribution, Drug Safety |
| Sep 14, 2011 |
Testimony of Allan Coukell before the Committee on Health Education Labor and Pensions, United States Senate"A major focus of the Pew Health Group is identifying ways to improve the safety of the U.S. pharmaceutical supply chain. In July of this year, we released a report entitled 'After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs.'" More info |
Drug Manufacturing and Distribution, Drug Safety |
| Mar 8, 2012 |
Testimony of Allan Coukell on the Lack of a National Pharmaceutical Tracking SystemOn March 8, 2012, Pew Health Group’s Director of Medical Programs Allan Coukell testified before the Energy and Commerce Committee’s Subcommittee on Health regarding the drug distribution system – the risks of counterfeit and stolen drugs, and the pragmatic steps Congress can take to reduce those risks. More info |
Drug Manufacturing and Distribution, Drug Safety |
| May 1, 2009 |
Testimony of Allan Coukell, Director of the Pew Prescription Project, on Protecting Consumers from Adulterated DrugsProtecting consumers against the risk of adulterated products is, of course, the original mission of the FDA. Today, the vast majority of pharmaceutical products sold in the United States today are not adulterated, but an increasingly complex supply chain creates new challenges and new risks – as recent events demonstrate. More info |
Drug Manufacturing and Distribution, Drug Safety |
| Jul 14, 2010 |
Testimony: Gail R. Hansen before the House Committee on Energy and Commerce, Subcommittee on HealthAntibiotics are overused in industrial farming to the detriment of human health. Antibiotic overuse has spurred generations of bacteria that are causing life threatening illnesses that were once easily treatable with antibiotics. Effective alternatives are available to agribusiness. Congress has the opportunity to enact legislation that will curtail the use of antibiotics in industrial food animal production without having significant economic impact on the industry. |
Antibiotics in Food Animal Production |
| Mar 19, 2010 |
Testimony: House Committee on Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related AgenciesAntibiotic-resistant infections have been identified by the Centers for Disease Control and Prevention (CDC) as one of the top public health challenges in the United States. Massive use of medically important antibiotics like penicillin and tetracycline in food animal production is a significant contributor to this problem. More info |
Antibiotics in Food Animal Production |
| Jul 15, 2009 |
Testimony: Robert P. Martin Before the U.S. House of Representatives Committee on RulesTestimony from Robert P. Martin, Senior Officer, Pew Environment Group, before the U.S. House of Representatives Committee on Rules regarding the Preservation of Antibiotics for Medical Treatment Act (PAMTA). More info |
Antibiotics in Food Animal Production |
| Aug 16, 2012 |
The Battle on the Home Front: The Jonathan Gadsden StorySince Operations Iraqi Freedom and Enduring Freedom began, many American servicemen and women have been infected with antibiotic-resistant bacteria. While our men and women in uniform increasingly survive severe wounds sustained in combat, their injuries leave them susceptible to life-threatening, hard-to-treat infections. Marine Lance Corporal Jonathan Gadsden’s story reflects the growing need for new antibiotics that can treat these dangerous diseases, against which most drugs are useless. More info |
Antibiotic Innovation |
| Mar 1, 2012 |
The Superbug ThreatAs Drug-resistant bacteria spread, the pipeline for antibiotics is drying up More info |
Antibiotic Innovation |
| Mar 1, 2012 |
The Threat of Multidrug-Resistant Infections to ChildrenExpert testimony, research, and commentary More info |
Antibiotic Innovation |
